Hugel (145020) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
11 Feb, 2026Executive summary
Net sales in 4Q25 reached KRW 119.1bn, up 21.3% year-over-year, with full-year 2025 sales at KRW 425.1bn, a 14.0% increase year-over-year.
Operating profit for 4Q25 was KRW 58.6bn, up 26.2% year-over-year, and full-year operating profit rose 21.3% to KRW 201.6bn.
Net income for 4Q25 was KRW 36.8bn, down 11.0% year-over-year, while full-year net income was KRW 144.0bn, up 0.6% year-over-year.
Financial highlights
Gross profit margin improved to 80.8% in 4Q25, up 3.7 percentage points year-over-year.
SG&A expenses increased 28.5% year-over-year in 4Q25, reaching KRW 37.6bn.
Operating margin for 4Q25 was 49.2%, up 1.9 percentage points year-over-year.
Outlook and guidance
International sales momentum is strong, with significant growth in North & South America and EU & Others.
Latest events from Hugel
- 3Q25 saw flat sales, lower profit, strong international growth, and robust Derma Cosmetics.145020
Q3 20254 Nov 2025 - Botulinum toxin and derma cosmetics drove double-digit sales growth, led by surging exports.145020
Q2 20256 Aug 2025 - Toxin and international sales drove 23.9% net sales growth and margin expansion.145020
Q3 202413 Jun 2025 - 2Q24 revenue and net income surged, led by toxin and filler growth in international markets.145020
Q2 202413 Jun 2025 - 1Q25 revenue and net income surged, led by strong Asia Pacific and product growth.145020
Q1 20256 Jun 2025 - Net income surged 130% year-over-year in 4Q24, with strong international sales growth.145020
Q4 20246 Jun 2025